AMWatch

Biotekfirma overvejer børs eller aktiesalg til kapitalfond

Det svenske biotekselskab Asarina Pharma med dank biotekprofil i spidsen står over for en kommende kapitalrejsning. Firmaet er i dialog med kapitalfond om investering, men overvejer også børsnotering.

Det svenske børsmarked har godt fat i life science-industrien, og alene i 2017 kiggede 36 selskaber mod børserne i Sverige i deres jagt på risikovillig kapital.

Nu kan endnu en virksomhed være på vej mod en børsnotering, for også selskabet Asarina Pharma overvejer netop nu, hvordan den skal finansiere et nyt forsøg med hovedkandidaten Sepranolone i en helt ny indikation, fortæller det svenske selskabs danske direktør Peter Nordkild.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

New paper slams model portfolio boom for conflict of interest

So-called model portfolios -- off-the-shelf investment strategies often comprising bundles of ETFs -- are ridden with conflicts of interest, according a trio of academics, including Associate Professor from the Norwegian School of Economics Nataliya Gerasimova.

Latest news

Jobs

Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch